Articles from Vyriad, Inc.

Vyriad, Inc., a clinical-stage biotechnology company developing targeted genetic therapies for cancer and other serious diseases, presented detailed data on its lentiviral vector retargeting technologies and its lead therapeutic in vivo chimeric antigen receptor (CAR) T program, VV169, at the recently concluded 67th American Society of Hematology (ASH) Annual Meeting.

Vyriad, Inc., a clinical-stage biotechnology company developing targeted genetic therapies for cancer and other serious diseases, and Yeda Research and Development Company, Ltd., the commercial arm of the Weizmann Institute of Science, today announced an exclusive license agreement for a novel viral vector targeting approach. The in vivo gene delivery technology, developed at the Weizmann Institute by professors Menachem Rubinstein, Gideon Schreiber, and Dr. Diana Gataulin, can improve vector specificity without compromising potency.